Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:37 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Ruboxistaurin in New York Heart Failure Classification III-IV Patients
NCT02769611 · University of Tennessee · PHASE1/PHASE2 · withdrawn · last registry update 2022-06-06 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “No funding” | – | Registry record, University of Tennessee |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PRKCB within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-10-06Also stopped (terminated): Insel Gruppe AG, University Hospital Bern, HDM201 + Midostaurin (NCT04496999)
- 2022-07-19Phase 3 first posted: Aytu BioPharma, Inc., Enzastaurin + Placebo (NCT05463679)
- 2022-05-25Also stopped (withdrawn): University Hospital Heidelberg, Quizartinib + Treatment according to Physician's Choice (NCT04676243)
- 2022-01-21Also stopped (terminated): University of Jena, Midostaurin (NCT03951961)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision